(Q46599505)

English

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine

scientific article published in March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Edwin DeJesus

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Peter Ruane

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Cheryl McDonald

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Fernando Garcia

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Shetal Sharma

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Roberto Corales

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Jayashree Ravishankar

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Homayoun Khanlou

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

David Shamblaw

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Janet Ecker

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Ramin Ebrahimi

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

John Flaherty

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

COMET Study Team

13

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

103-114

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Adherence to HAART Regimens

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Switching effective antiretroviral therapy: a review.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Prevalence and clinical correlates of HIV viremia (`blips') in patients with previous suppression below the limits of quantification

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Transient Viremia in HIV-Infected Patients and Use of Plasma Preparation Tubes

1 reference

https://api.crossref.org/works/10.1310%2FHCT0902-103

21 January 2018

Identifiers

10.1310/HCT0902-103

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

release_2dgipo6gvracbcizz2mjschzgu

1 reference

https://api.fatcat.wiki/v0/release/2dgipo6gvracbcizz2mjschzgu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18474495

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46599505&oldid=2121379325"